Global Leading Market Research Publisher QYResearch announces the release of its latest report “AI Chronic Disease Management – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global AI Chronic Disease Management market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for AI Chronic Disease Management was estimated to be worth US$ 1835 million in 2025 and is projected to reach US$ 5893 million, growing at a CAGR of 18.4% from 2026 to 2032.
AI chronic disease management uses artificial intelligence (AI) to digitally and intelligently manage the entire lifecycle of chronic diseases (such as diabetes, hypertension, coronary heart disease, and chronic obstructive pulmonary disease). Its core approach involves real-time collection and analysis of patients’ electronic medical records, test data, wearable device monitoring information, and lifestyle data through big data, machine learning, natural language processing, knowledge graphs, and intelligent algorithms. This enables disease risk prediction, personalized intervention, medication guidance, rehabilitation tracking, and remote follow-up. Compared to traditional manual management, AI chronic disease management can significantly improve diagnosis and treatment efficiency, reduce physician burden, lower medical costs, and help patients develop long-term healthy behaviors. It has broad application value in smart hospitals, internet medical platforms, medical insurance cost control, and family health management, and is a key direction for the future development of digital healthcare and precision medicine.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097362/ai-chronic-disease-management
1. Industry Pain Points and the Shift Toward AI-Powered Chronic Care
Chronic diseases (diabetes, hypertension, COPD, heart disease) affect over 1.5 billion people globally and account for 70-80% of healthcare costs. Traditional manual management is reactive, episodic (clinic visits every 3-6 months), and fails to capture daily fluctuations in patient status. AI chronic disease management addresses this through continuous real-time monitoring (wearables, connected devices), predictive analytics (risk stratification), and personalized interventions (medication adjustments, lifestyle coaching). For healthcare systems, payers, and providers, AI-driven chronic care reduces hospital readmissions (by 30-50%), improves medication adherence (by 20-40%), and lowers overall cost of care.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global AI chronic disease management market was valued at US$ 1.835 billion in 2025 and is projected to reach US$ 5.893 billion by 2032, growing at a CAGR of 18.4%. Market hyper-growth is driven by three factors: increasing prevalence of chronic diseases (aging population, lifestyle factors), expansion of value-based care and telehealth (post-COVID acceleration), and AI algorithm advancements (deep learning, LLMs for patient engagement).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four explosive developments:
- CGM-AI integration: Dexcom and Glooko integrated continuous glucose monitor (CGM) data with AI insulin dosing algorithms (e.g., Omada, Virta), reducing hypoglycemia events by 40%. AI-CGM segment grew 35% year-over-year.
- LLM-based patient coaching: New large language models (Teladoc, Xunfei Healthcare) provide 24/7 conversational coaching for medication adherence and lifestyle changes. LLM coaching segment grew 50% in 2025.
- Remote patient monitoring (RPM) reimbursement expansion: CMS expanded RPM codes (99457, 99458) for AI-powered chronic care, driving 25% growth in virtual chronic care programs.
- Chinese market expansion: Alibaba Group, Ping An Insurance, Fangzhou Inc, Jianhai Technology, Lepu Medical, Sinocare, and Xunfei Healthcare launched integrated AI chronic disease platforms, capturing Asia-Pacific market share.
4. Competitive Landscape and Key Suppliers
The market includes digital health platforms, CGM/wearable manufacturers, and healthcare IT providers:
- Teladoc Health (US), S3 Connected Health (Ireland), Cognizant (US), Omada Health (US), WellDoc (US), Epic Systems (US), Pathmate (US), EveryDose (US), Aptar Digital Health (US/France), VITech (US), Virta Health (US), Glooko (US), Dexcom (US), Philips (Netherlands), Siemens (Germany), Assure Tech (China), Alibaba Group (China), Ping An Insurance (China), Fangzhou Inc (China), Jianhai Technology (China), Lepu Medical (China), Sinocare (China), Xunfei Healthcare (China).
Competition centers on three axes: AI algorithm accuracy (prediction, risk stratification), patient engagement (retention, adherence), and integration with EMR/RPM systems.
5. Segment-by-Segment Analysis: Type and Application
By Platform Type
- Mobile Applications: Largest segment (~45% of market). Patient-facing apps for self-management (medication reminders, symptom tracking, coaching).
- Wearable Hardware: (~30% of market). CGM (Dexcom), smartwatches (Apple, Fitbit), BP monitors, pulse oximeters. Fastest-growing segment (CAGR 20%).
- Cloud Platform: (~20% of market). Backend AI analytics, provider dashboards, population health management.
- Others: (~5% of market).
By End User
- Home: Largest segment (~50% of market). Direct-to-consumer chronic disease management (diabetes, hypertension).
- Medical: (~30% of market). Provider-led programs (health systems, accountable care organizations).
- Commercial: (~15% of market). Employer-sponsored wellness programs, health plans.
- Others: ~5% of market.
User case – AI diabetes management (Omada Health) : A health plan enrolled 10,000 prediabetic members in Omada’s AI-powered program (CGM + app + coaching). Over 12 months: average weight loss 5.2%, HbA1c reduction 0.4%, 30% reduction in diabetes progression. Program cost: US$ 600/member/year. Estimated healthcare savings: US$ 2,400/member/year (ROI 4:1).
6. Exclusive Insight: AI Capabilities in Chronic Disease Management
| Disease | AI Application | Data Sources | Clinical Impact |
|---|---|---|---|
| Diabetes | Insulin dose titration, hypoglycemia prediction | CGM, insulin pump, food logs | 40% reduction in hypoglycemia |
| Hypertension | Medication adherence coaching, BP trend analysis | Home BP monitor, pharmacy data | 15% improvement in BP control |
| COPD | Exacerbation prediction, inhaler technique feedback | Spirometry, oxygen saturation, activity tracking | 30% reduction in hospitalizations |
| Heart failure | Weight tracking, symptom monitoring, readmission risk | Smart scale, wearable, patient-reported outcomes | 25% reduction in readmissions |
| Mental health | Mood tracking, intervention delivery | Smartphone, wearable, self-reports | 40% improvement in depression scores |
Technical challenge: Ensuring AI safety for treatment decisions (e.g., insulin dosing). Black-box algorithms can produce dangerous recommendations. Solutions include:
- Explainable AI (XAI) : Provide reasoning for recommendations
- Human-in-the-loop: Clinician oversight for high-risk decisions
- Continuous learning with guardrails: Limit algorithm updates to safe ranges
- Regulatory approval: FDA clearance for AI therapeutic recommendations (e.g., insulin dosing)
User case – FDA-approved AI insulin dosing: Virta Health’s AI insulin titration algorithm received FDA clearance (2025). The algorithm recommends insulin dose adjustments based on CGM data, meal logs, and activity. Clinician approves or modifies recommendation via dashboard. In clinical trial (n=500), time-in-range increased from 55% to 75% with no severe hypoglycemia.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (45% share, CAGR 18%). US (Teladoc, Omada, WellDoc, Epic, Dexcom, Glooko, VITech, Virta, Aptar, Cognizant). Strong digital health adoption, RPM reimbursement.
- Europe: Second-largest (25% share, CAGR 17%). Germany (Siemens), Netherlands (Philips), Ireland (S3). Strong digital health infrastructure.
- Asia-Pacific: Fastest-growing region (CAGR 20%). China (Alibaba, Ping An, Fangzhou, Jianhai, Lepu, Sinocare, Xunfei, Assure Tech). Large chronic disease population, government digital health initiatives.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The AI chronic disease management market is positioned for explosive growth through 2032, driven by chronic disease prevalence, value-based care, and AI algorithm advancements. Stakeholders—from digital health platforms to payers—should prioritize CGM/wearable integration for continuous monitoring, LLM-based coaching for patient engagement, and FDA clearance for AI therapeutic recommendations. By enabling personalized interventions and remote monitoring, AI chronic disease management improves outcomes and reduces costs.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
